The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...

FC Barcelona hired Goldman Sachs Group Inc. to explore ways to reduce the cost of the debt used for the ongoing revamp of the ...

Hedge funds unwound positions in single stocks on Friday at the largest amount in over two years, with some activity ...

Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

S&P 500 E-Mini futures (ESH25) are down -0.92%, and March Nasdaq 100 E-Mini futures (NQH25) are down -1.14% this morning as higher Treasury yields, trade war worries, and disappointing tech earnings ...

Goldman Sachs is no longer spelling out its diversity hiring targets. The bank’s annual report no longer lays out the progress it has made on hiring women, Black, Hispanic, Asian and LGBTQ+ ...

Moderna shares fell more than 5% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine.

Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Moderna with a target price of $78. * In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral ...

Trump Administration Weighs Pulling Funding for Moderna Bird Flu Vaccine, Bloomberg News Reports (Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to ...

Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Finally, The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and ...